Combined Inhibition of IAPs and WEE1 Enhances TNFα- and Radiation-Induced Cell Death in Head and Neck Squamous Carcinoma

• Published in: Cancers 2023-02, Vol.15 (4), p.1029
• Main Authors: Toni, Tiffany, Viswanathan, Ramya, Robbins, Yvette, Gunti, Sreenivasulu, Yang, Xinping, Huynh, Angel, Cheng, Hui, Sowers, Anastasia L, Mitchell, James B, Allen, Clint T, Morgan, Ethan L, Van Waes, Carter
• Format: Article
• Language: English
• Subjects: Antibodies; Apoptosis; Cancer therapies; Care and treatment; Cell cycle; Cell death; Cell proliferation; Cell survival; Cell viability; Clinical trials; Cytotoxicity; DNA damage; Dosage and administration; Enzyme inhibitors; Head and neck cancer; Head and neck carcinoma; Human papillomavirus; IAP protein; Infrared imaging systems; Kinases; Medical prognosis; Methods; NF-κB protein; Phosphatase; Proteins; Radiation therapy; Radiotherapy; Squamous cell carcinoma; Tumor necrosis factor-α
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15041029

Head and neck squamous cell carcinoma (HNSCC) remains a prevalent diagnosis with current treatment options that include radiotherapy and immune-mediated therapies, in which tumor necrosis factor-α (TNFα) is a key mediator of cytotoxicity. However, HNSCC and other cancers often display TNFα resistance due to activation of the canonical IKK-NFκB/RELA pathway, which is activated by, and induces expression of, cellular inhibitors of apoptosis proteins (cIAPs). Our previous studies have demonstrated that the IAP inhibitor birinapant sensitized HNSCC to TNFα-dependent cell death in vitro and radiotherapy in vivo. Furthermore, we recently demonstrated that the inhibition of the G2/M checkpoint kinase WEE1 also sensitized HNSCC cells to TNFα-dependent cell death, due to the inhibition of the pro-survival IKK-NFκB/RELA complex. Given these observations, we hypothesized that dual-antagonist therapy targeting both IAP and WEE1 proteins may have the potential to synergistically sensitize HNSCC to TNFα-dependent cell death. Using the IAP inhibitor birinapant and the WEE1 inhibitor AZD1775, we show that combination treatment reduced cell viability, proliferation and survival when compared with individual treatment. Furthermore, combination treatment enhanced the sensitivity of HNSCC cells to TNFα-induced cytotoxicity via the induction of apoptosis and DNA damage. Additionally, birinapant and AZD1775 combination treatment decreased cell proliferation and survival in combination with radiotherapy, a critical source of TNFα. These results support further investigation of IAP and WEE1 inhibitor combinations in preclinical and clinical studies in HNSCC.